Atsushi Usami
Partner & Board Director @ UTEC - The University of Tokyo Edge Capital Partners
Tokyo, Japan
Atsushi Usami is a Series B investor at UTEC - The University of Tokyo Edge Capital Partners in Tokyo focused on Health Care and Biotechnology. Atsushi Usami is based out of Tokyo, Tokyo and is the Partner & Board Director of UTEC – The University of Tokyo Edge Capital Partners. Atsushi previously worked at Mitsubishi Research Institute as a researcher. Atsushi Usami attended The University of Tokyo.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 60%
Last updated:
For AI agents: llms.txt
Industries Atsushi Usami invests in
Stages Atsushi Usami invests in
Countries Atsushi Usami invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 5 (33%)
- Biotechnology 5 (33%)
- Medical 4 (27%)
- Life Science 3 (20%)
- Therapeutics 2 (13%)
Stage
- Series B 5 (33%)
- Seed 4 (27%)
- Series A 3 (20%)
- Pre-Seed 1 (7%)
Country
- Japan 5 (33%)
- India 1 (7%)
- United States 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| RegCell aims to generate novel therapeutic technologies through augmenting or controlling the immune system and our goal is to save patients who suffer from autoimmune diseases and cancer . | $44M / Series A / Sep 15, 2026 | ||
| Celaid Therapeutics develops technologies and products based on hematopoietic stem cell (HSC) expansion and gene-augmented therapies. The company operates a platform that enables in-vitro propagation of human HSCs without relying on animal-derived components, facilitating scalability, consistency, and cost control. It applies this platform acrossworkflows, including donor/patient cell collection, HSC expansion, cell processing, and gene editing to deliver cell therapy products. Celaid advances pipelines in areas such as blood cancers, genetic disorders, and rare hematologic diseases. Through partnerships and internal research, it seeks to support both reagent/media supply and therapeutic development around HSC-based regenerative medicine. | $3.6M / Series B / Oct 07, 2025 | ||
| Pahr Therapeutics is a clinical-stage business whose goal is to create innovative ways to treat pulmonary arterial hypertension. | $14M / Seed / Jul 28, 2025 | ||
| RegCell aims to generate novel therapeutic technologies through augmenting or controlling the immune system and our goal is to save patients who suffer from autoimmune diseases and cancer . | $8.5M / Seed / Mar 18, 2025 | ||
| Celaid Therapeutics develops technologies and products based on hematopoietic stem cell (HSC) expansion and gene-augmented therapies. The company operates a platform that enables in-vitro propagation of human HSCs without relying on animal-derived components, facilitating scalability, consistency, and cost control. It applies this platform acrossworkflows, including donor/patient cell collection, HSC expansion, cell processing, and gene editing to deliver cell therapy products. Celaid advances pipelines in areas such as blood cancers, genetic disorders, and rare hematologic diseases. Through partnerships and internal research, it seeks to support both reagent/media supply and therapeutic development around HSC-based regenerative medicine. | $3M / Series A / May 08, 2024 | ||
| Violet Therapeutics is a healthcare company that operates in stealth mode. | $10.6M / Seed / May 05, 2023 | ||
| OriCiro Genomics creates a better bioeconomy with innovative genome technologies. The company is a pioneer in cell-free synthesis and amplification of genome-scale large DNA for synthetic biology.The company creates a technology that covers "DNA assembly" and "circular DNA amplification", allowing to construct large circularDNA molecules without relying on conventional biological cloning. | Series B / Jun 05, 2022 | ||
| BUGWORKS is a drug discovery company that aims to discover novel pharmaceutical assets for combating Antimicrobial Resistance (AMR). The company was founded in 2014 and is based in Bangalore, India. | $18M / Series B / Feb 09, 2022 | ||
| OriCiro Genomics creates a better bioeconomy with innovative genome technologies. The company is a pioneer in cell-free synthesis and amplification of genome-scale large DNA for synthetic biology.The company creates a technology that covers "DNA assembly" and "circular DNA amplification", allowing to construct large circularDNA molecules without relying on conventional biological cloning. | $7.3M / Series B / Jul 20, 2021 | ||
| Metcela is a clinical-stage biotech startup providing patients with an innovative and alternative treatment option for heart disease. The company's lead asset, MTC001 is a cell therapy based on VCAM-1-positive Cardiac Fibroblast (VCF) that re-established a favorable microenvironment and repaired damaged heart tissues in preclinical studies.Metcela's therapy uses a specific fibroblast cell that is obtained from the patient's heart and instead of replacing them, it repairs the damage by enhancing the cells' ability to heal, providing patients with an effective and reasonably-priced cure for heart failure.It was founded on March 9, 2016, and is headquartered in Kawasaki, Japan. | $12.7M / Series B / Jan 04, 2021 | ||
| See all 15 investments → | |||
Co-Investors
UTEC - The University of Tokyo Edge Capital Partners, is a Japan-based seed/early stage deep-tech venture capital firm associated with academic institutes such as The University of Tokyo. UTEC has over $1 billion in Assets Under Management, and has invested in 150+ companies in Japan, USA, Singapore, India and Europe with a track record of 20 IPOs and 22 successful M&A (as of Nov 2025). UTEC predominantly invests in three deep-tech sectors: a) Healthcare & Life Sciences, b) IT/AI, and c) Physical Sciences & Engineering.
UTEC - The University of Tokyo Edge Capital Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Atsushi Usami
Partner & Board Director
|
|||
Hiroaki Kobayashi
Principal
|
|||
Keisuke Ide
Partner
|
|||
Kiran Mysore
Principal
|
|||
Maiko Katadae
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Atsushi Usami invest in?
Atsushi Usami invests primarily in Health Care, Biotechnology and Medical startups, most often at Series B and Seed stage. Most of the 15 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Atsushi Usami?
Public channels for Atsushi Usami include LinkedIn, X (Twitter) and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Atsushi Usami last invest?
The most recent investment recorded for Atsushi Usami closed in Sep 2026. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
